Literature DB >> 1846215

The occupational risk of cytomegalovirus infection among day-care providers.

J R Murph1, J C Baron, C K Brown, C L Ebelhack, J F Bale.   

Abstract

We prospectively studied day-care providers at six day-care centers in south-eastern Iowa to determine their occupational risk for primary cytomegalovirus infection and to define epidemiologic risk factors. Ninety-six (38%) of 252 day-care providers were seropositive for cytomegalovirus by latex agglutination at entry into the study. Among 82 seronegative providers available for follow-up, seven seroconversions occurred at only two of the six participating centers, yielding an annualized seroconversion rate of 7.9%. Median time to seroconversion among these providers was 13 months. Using Kaplan-Meier estimates of risk, we determined that the overall risk of seroconversion among providers at various centers ranged from 0% to 22% by 12 months and from 0% to 40% by 16 months. Risk of cytomegalovirus acquisition by providers was independent of race, age, education, the presence of a child at home, or caring for children younger than 2 or 3 years in the day-care center. However, the risk of seroconversion among day-care providers appeared to parallel rates of cytomegalovirus excretion and acquisition among children at each center.

Entities:  

Mesh:

Year:  1991        PMID: 1846215

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  28 in total

1.  Does cytomegalovirus present an occupational risk?

Authors:  P Tookey; C S Peckham
Journal:  Arch Dis Child       Date:  1991-09       Impact factor: 3.791

Review 2.  Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection.

Authors:  Michael J Cannon; Terri B Hyde; D Scott Schmid
Journal:  Rev Med Virol       Date:  2011-06-15       Impact factor: 6.989

3.  Cytomegalovirus infection in newborns and their family members: polymerase chain reaction analysis of isolates.

Authors:  I E Souza; A Gregg; D Pfab; J D Dawson; P Benson; M E O'Neill; J R Murph; S J Petheram; J F Bale
Journal:  Infection       Date:  1997 May-Jun       Impact factor: 3.553

4.  Salivary antibodies to cytomegalovirus (CMV) glycoprotein B accurately predict CMV infections among preschool children.

Authors:  J B Wang; S P Adler
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

5.  Characterization of human cytomegalovirus strains by analysis of short tandem repeat polymorphisms.

Authors:  A Walker; S J Petheram; L Ballard; J R Murph; G J Demmler; J F Bale
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

Review 6.  The "silent" global burden of congenital cytomegalovirus.

Authors:  Sheetal Manicklal; Vincent C Emery; Tiziana Lazzarotto; Suresh B Boppana; Ravindra K Gupta
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

7.  qPCR is a sensitive and rapid method for detection of cytomegaloviral DNA in formalin-fixed, paraffin-embedded biopsy tissue.

Authors:  Morgan H McCoy; Kristin Post; Joyashree D Sen; Hsim Y Chang; Zijin Zhao; Rong Fan; Shaoxiong Chen; Diane Leland; Liang Cheng; Jingmei Lin
Journal:  J Vis Exp       Date:  2014-07-09       Impact factor: 1.355

8.  Occupational risk of human Cytomegalovirus and Parvovirus B19 infection in female day care personnel in the Netherlands; a study based on seroprevalence.

Authors:  F F Stelma; A Smismans; V J Goossens; C A Bruggeman; C J P A Hoebe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-11       Impact factor: 3.267

9.  Cytomegalovirus prevalence in pregnant women: the influence of parity.

Authors:  P A Tookey; A E Ades; C S Peckham
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

10.  Cytomegalovirus as an occupational risk in daycare educators.

Authors:  Serene A Joseph; Claire Béliveau; Cristin J Muecke; Elham Rahme; Julio C Soto; Gordon Flowerdew; Lynn Johnston; Donald Langille; Theresa W Gyorkos
Journal:  Paediatr Child Health       Date:  2006-09       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.